All In Biotech

Drug Trial Radar · NCT07285044

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Dec 18, 2025

Primary completion

May 15, 2027

Study completion May 15, 2027

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.

Conditions

  • Amyloidosis
  • Basal Cell Carcinoma
  • Biliary Tract Carcinoma
  • Bladder Carcinoma
  • Breast Carcinoma
  • Cervical Carcinoma
  • Colorectal Carcinoma
  • Endometrial Carcinoma
  • Fallopian Tube Carcinoma
  • Gastroesophageal Junction Carcinoma
  • Glioblastoma
  • Head and Neck Carcinoma
  • Hematopoietic and Lymphatic System Neoplasm
  • Hepatocellular Carcinoma
  • Hodgkin Lymphoma
  • Lung Carcinoma
  • Malignant Solid Neoplasm
  • Mantle Cell Lymphoma
  • Melanoma
  • Merkel Cell Carcinoma
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Ovarian Carcinoma
  • Pancreatic Carcinoma
  • Primary Peritoneal Carcinoma
  • Prostate Carcinoma
  • Renal Cell Carcinoma
  • Squamous Cell Carcinoma
  • Urothelial Carcinoma

Interventions

  • Cancer Therapeutic ProcedureDrug

    Receive in-home standard of care cancer-treatment

  • Cancer Therapeutic ProcedureDrug

    Receive in-clinic standard of care cancer-treatment

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient preferences regarding location of cancer treatment deliveryTime frame: At 12 weeks
  2. Adverse Events Related to Location of TreatmentTime frame: Up to 9 months
  3. Incidence of avoidable acute care visits, emergency room visits, and hospitalizationsTime frame: Up to 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.